Professional Biography
Image of James Lisbakken

James R. Lisbakken Partner

Firmwide Co-Chair, Life Sciences Industry Group

  • Seattle

    D +1.206.359.8660

    F +1.206.359.9660


    1201 Third Avenue, Suite 4900

    Seattle, WA






Technology Transactions & Privacy

MedImmune LLC In-Licenses Immune Design Corporation's Adjuvant

Represented Immune Design Corporation in agreement with MedImmune LLC granting MedImmune exclusive, worldwide rights to develop and commercialize Immune Design's glucopyranosyl lipid adjuvant (GLA) as a component in vaccines for undisclosed indications. As a result of the deal Immune Design is eligible for $212 million, including an upfront payment and milestones, and is also eligible to receive royalties. MedImmune is a subsidiary of AstraZeneca plc (NYSE:AZN; LSE:AZN). GLA is a toll-like receptor 4 (TLR-4) agonist has completed Phase I testing.

Life Sciences

Corporate Collaborations and License Agreements

Represented clients in numerous corporate collaborations and license agreements with such companies as Glaxo, Eli Lilly, Bristol-Myers Squibb, MedImmune, Teva, Serono, Novo Nordisk, Abbott, Bayer, Kissei, and Kirin.

Research Institutions License Agreements

Represented clients in license agreements or sponsored research agreements with research institutions such as University of Washington, Fred Hutchinson Cancer Research Center, MIT, University of Texas Southwestern, and Mayo Clinic.

Joint Venture Agreements

Represented ICOS Corporation in its major joint venture and related agreements with Eli Lilly for the development and commercialization of the ICOS compound known as Cialis.

Corporate Collaboration

Represented ZymoGentics in its corporate collaboration with Bristol-Myers Squibb for the development and commercialization of interferon lambda under which it could receive milestone payments in excess of one billion dollars.

Outside General Counsel and Board Advisor

Acted as outside general counsel and board advisor to seven public life sciences companies.

ZymoGenetics Inc.

Represented ZymoGenetics in its initial public offering and subsequent offerings of common stock.


Common Stock Offering

Represented ICOS Corporation, ZymoGenetics, Eden and other companies in their initial public offering and subsequent offerings of common stock.

Venture Equity, Debt, Sales of Royalty Streams

Represented clients in receiving financing in the form of venture equity, debt, sales of royalty streams and R&D partnerships.


Represented Darwin Molecular, Ostex, Procyte, Alcide and others in connection with their acquisitions by larger companies.